Table S1. Correlation of EASIX with variables being assessed and characteristics of patients with high EASIX (≥2.36) and low EASIX (<2.36). Parameters and quantitative variables are presented as median [interquartile range - IQR]; qualitative variables are presented as frequency/number.

	EASIX *p*-value	High EASIX	Low EASIX	*p*-value
Variable		*n* = 111	*n* = 258	
Male	**<0.001**	82 (73.9%)	159 (66.0%)	**0.023**
Age	0.125	68 [61–76]	68 [60–74]	0.639
Death	**<0.001**	95 (85.6%)	148 (57.4%)	**<0.001**
Concomitant diseases				
Cardiovascular diseases	**<0.001**	87 (78.4%)	163 (63.2%)	**0.004**
Hypertension	**<0.001**	82 (73.9%)	148 (%)	**0.003**
Atrial fibrilation	0.110	17 (15.3%)	**30 (11.6%)**	0.330
Ischemic heart disease	0.050	34 (30.6%)	**52 (20.2%)**	**0.029**
Pulmonary diseases	0.345	8 (7.2%)	28 (10.9%)	0.279
Asthma	0.894	5 (4.5%)	14 (5.4%)	0.713
COPD	0.951	3 (2.7%)	8 (3.1%)	0.837
Other	0.424	2 (1.8%)	6 (2.3%)	0.751
Diabetes	0.223	46 (41.4%)	88 (34.1%)	0.179
Malignant neoplasm	**0.033**	13 (11.7%)	44 (17.1%)	0.193
Chronic kidney disease	**<0.001**	25 (22.3%)	8 (3.1%)	**<0.001**
Obesity	0.925	31 (27.9%)	74 (28.7%)	0.883
SpO$_2$ without oxygen supply	**0.014**	83 [70–90]	87 [82–92]	**<0.001**
Severity (according to WHO scale) 1 2 3 4	**0.027**	1 (0.9%) 27 (24.3%) 64 (57.7%) 19 (17.1%)	4 (1.6%) 76 (29.5%) 157 (60.8%) 21 (8.1%)	0.076
Duration of hospitalisation, days	**0.019**	12 [6–20]	18 [12–25]	**<0.001**
Duration of symptoms before hospital admission, days	0.549	6 [4–8]	7 [5–9]	0.181
Deterioration, days (from disease onset)	**<0.001**	7 [4–9]	8 [5–12]	**0.002**
ICU admission	**0.026**	80 (72.1%)	135 (52.3%)	**0.001**
ICU admission, days (from disease onset)	**0.032**	9 [7–16]	12 [8–17]	0.102
ICU admission, days (from hospitalisation onset)	**0.042**	3 [1–7]	4 [2–8]	0.062
ICU duration, days	**<0.001**	9 [6–17]	13 [8–20]	**0.009**
Non-rebreather mask 10-15l/min	0.764	104 (93.7%)	247 (95.7%)	0.403
Non-rebreather mask 10-15l/min duration, days	**<0.001**	1 [0–2]	2 [1–3]	**<0.001**
HFNO	0.622	72 (64.9%)	181 (70.2%)	0.315
HFNO duration, days	**<0.001**	2 [1–6]	5 [2–9]	**<0.001**
NIV	0.271	24 (21.8%)	45 (17.4%)	0.325
NIV duration, days	0.835	3 [1–5]	4 [1–7]	0.604
IMV	**<0.001**	82 (74.6%)	137 (53.1%)	**<0.001**
IMV duration, days	**0.008**	8 [5–16]	12 [7–19]	**0.006**

	Lab test results			
CRP	**0.001**	143.2 [78.5–214.7]	112.3 [55.7–188.5]	**0.012**
Procalcitonin	**<0.001**	0.722 [0.283–2.89]	0.157 [0.084–0.474]	**<0.001**
Ferritin	**<0.001**	2137.8 [985.3–3608.3]	1037 [526.7–1611.6]	**<0.001**
LDH	**<0.001**	685 [530–897]	471 [376–592]	**<0.001**
White blood count	**0.003**	7.06 [5.13–9.55]	8.04 [5.81–10.78]	0.079
Neutrophils	**0.011**	5.6 [4.05–8]	6.6 [4.2–8.9]	0.147
Lymphocytes	**0.021**	0.8 [0.6–1.1]	0.9 [0.6–1.2]	0.067
Haemoglobin	0.326	13.3 [11.6–14.7]	13.4 [12.3–14.7]	0.608
Thrombocytes	**<0.001**	159 [128–196]	223 [170–297]	**<0.001**
D-dimer	**0.030**	2017 [1037–3326]	1264 [822–2424]	**<0.001**
INR	**0.042**	1.12 [1.04–1.3]	1.08 [1.01–1.16]	**0.001**
AST	**<0.001**	69.4 [46.6–105]	50 [36.2–67.8]	**<0.001**
ALT	0.146	42 [25.9–69]	38 [25–63.3]	0.313
Creatinine	**<0.001**	1.71 [1.28–2.4]	0.91 [0.76–1.13]	**<0.001**

Table S2. Correlation of mEASIX with the variables being assessed and characteristics of patients with high mEASIX (≥704.05) and low mEASIX (<704.05). Parameters and quantitative variables are presented as median [interquartile range— IQR]; qualitative variables are presented as frequency/number.

	mEASIX p-value	High mEASIX	Low mEASIX	p-value
Variable		n = 124	n = 246	
Male	**<0.001**	93 (75.0%)	149 (60.6%)	**0.006**
Age	**0.032**	67 [60–74]	68 [61–74.5]	0.682
Death	**<0.001**	91 (73.4%)	152 (61.8%)	**0.027**
	Concomitant diseases			
Cardiovascular diseases	0.334	89 (71.8%)	162 (65.9%)	0.569
Hypertension	0.672	79 (63.7%)	152 (61.8%)	0.719
Atrial fibrilation	0.484	21 (16.9%)	26 (10.6%)	0.083
Ischemic heart disease	0.723	32 (25.8%)	54 (22.0%)	**0.407**
Pulmonary diseases	0.608	11 (8.9%)	25 (10.2%)	0.692
Asthma	0.388	9 (7.3%)	10 (4.1%)	0.189
COPD	0.875	3 (2.4%)	8 (3.3%)	0.656
Other	0.196	1 (0.8%)	7 (2.8%)	0.203
Diabetes	0.474	46 (37.1%)	88 (35.8%)	0.802
Malignant neoplasm	**0.026**	16 (12.9%)	41 (16.7%)	0.344
Chronic kidney disease	0.793	8 (6.5%)	24 (9.8%)	0.286
Obesity	0.843	33 (26.6%)	72 (29.3%)	0.593
SpO$_2$ without oxygen supply	**<0.001**	80 [68–88]	87 [81–92]	**<0.001**
Severity (according to WHO scale)	0.296			**<0.001**
1		0 (0.0%)	5 (2.0%)	
2		17 (13.7%)	86 (35.0%)	
3		87 (70.2%)	135 (54.9%)	
4		20 (16.1%)	20 (8.1%)	
Duration of hospitalisation, days	0.226	12 [5–20]	17 [11–25]	**<0.001**
Duration of symptoms before hospital admission, days	**0.025**	7 [5–8]	7 [4–9]	0.617
Deterioration, days (from disease onset)	0.064	7 [5–9]	8 [5–10]	0.199
ICU admission	**0.019**	84 (67.7%)	132 (53.7%)	**0.017**

	sEASIX p-value			
ICU admission, days (from disease onset)	0.098	9 [6.5–15]	12 [7–17]	0.050
ICU admission, days (from hospitalisation onset)	0.241	2 [0–4]	5 [2–8]	**<0.001**
ICU duration, days	0.134	11 [5–18]	11.5 [6–18]	0.314
Non-rebreather mask 10-15l/min	0.127	114 (91.9%)	238 (96.8%)	**0.042**
Non-rebreather mask 10-15l/min duration, days	0.321	1 [0–2]	2 [1–3]	**<0.001**
HFNO	0.959	79 (63.7%)	174 (70.7%)	0.170
HFNO duration, days	0.126	2 [1–5]	5 [2–9]	**<0.001**
NIV	0.133	27 (21.8%)	42 (17.1%)	0.273
NIV duration, days	0.057	3 [2–5]	4 [1–6]	0.741
IMV	0.138	87 (70.2%)	133 (54.1%)	**0.003**
IMV duration, days	0.178	10 [4–16]	11 [6–18]	0.062
Lab test results				
CRP	**<0.001**	233.3 [180.2–296.1]	96.4 [51.6–155.7]	**<0.001**
Procalcitonin	**<0.001**	0.91 [0.25–1.69]	0.16 [0.07–0.49]	**<0.001**
Ferritin	**<0.001**	2321 [979–4474]	1086 [546–1750]	**<0.001**
LDH	**<0.001**	777 [588–954]	476 [374–602]	**<0.001**
White blood count	0.245	8.18 [5.49–11.08]	7.55 [5.51–10.34]	0.671
Neutrophils	**0.003**	6.7 [4.6–10.0]	6 [3.9–8.6]	0.162
Lymphocytes	**<0.001**	0.7 [0.5–0.9]	0.9 [0.6–1.2]	**0.004**
Haemoglobin	0.711	13.3 [10.9–14.6]	13.4 [12.2–14.7]	0.216
Thrombocytes	**<0.001**	153 [123–204]	211 [163–281]	**<0.001**
D-dimer	**<0.001**	2180 [1173–3950]	1258 [797–2426]	**<0.001**
INR	**<0.001**	1.14 [1.05–1.22]	1.08 [1.0–1.1]	**0.002**
AST	**<0.001**	74 [52–106]	50 [36–69]	**<0.001**
ALT	**<0.001**	46 [31–82]	37 [25–61]	**0.005**
Creatinine	**<0.001**	1.36 [0.98–1.79]	0.99 [0.79–1.29]	**<0.001**

Table S3. Correlation of sEASIX with variables being assessed and characteristics of patients with high sEASIX (≥3.81) and low sEASIX (<3.81). Parameters and quantitative variables are presented as median [interquartile range—IQR]; qualitative variables are presented as frequency/number.

	sEASIX *p*-value	High sEASIX	Low sEASIX	*p*-value
Variable		*n* = 91	*n* = 279	
Male	0.052	60 (66.7%)	182 (65.2%)	0.903
Age	0.087	68 [60–74]	68 [61–75]	0.582
Death	**<0.001**	77 (84.6%)	166 (59.5%)	**<0.001**
Concomitant diseases				
Cardiovascular diseases	**0.027**	69 (75.8%)	182 (65.2%)	0.060
Hypertension	0.319	65 (72.2%)	166 (59.5%)	0.051
Atrial fibrilation	0.411	14 (15.6%)	33 (11.8%)	0.376
Ischemic heart disease	0.644	23 (25.6%)	63 (22.6%)	0.597
Pulmonary diseases	0.782	10 (11.0%)	26 (9.3%)	0.641
Asthma	0.358	7 (7.8%)	12 (4.3%)	0.203
COPD	0.963	3 (3.3%)	8 (2.9%)	0.834
Other	0.948	2 (2.2%)	6 (2.2%)	0.979
Diabetes	0.658	36 (39.6%)	98 (35.1%)	0.614
Malignant neoplasm	**0.046**	15 (16.5%)	42 (15.1%)	0.743
Chronic kidney disease	0.420	11 (12.1%)	22 (7.9%)	0.222
Obesity	0.799	22 (24.2%)	83 (29.8%)	0.306
SpO$_2$ without oxygen supply	**0.001**	84 [72–90]	87 [80–92]	**0.015**

Severity (according to WHO scale)	0.095			**0.049**
1		1 (1.1%)	4 (1.4%)	
2		22 (24.4%)	81 (29.1%)	
3		51 (56.6%)	171 (61.3%)	
4		17 (18.9%)	23 (8.2%)	
Duration of hospitalisation, days	0.160	13.5 [7–21]	17 [11–25]	**0.003**
Duration of symptoms before hospital admission, days	0.949	7 [5–8]	7 [4–9]	0.860
Deterioration, days (from disease onset)	0.089	7 [5–9]	8 [5–11]	0.306
ICU admission	**0.001**	66 (73.3%)	150 (53.8%)	**0.004**
ICU admission, days (from disease onset)	0.078	10 [7–15.5]	12 [7–17]	0.301
ICU admission, days (from hospitalisation onset)	0.154	3 [0–6]	4 [2–8]	**0.033**
ICU duration, days	**0.035**	11 [6–17.5]	11 [6–18]	0.621
Non-rebreather mask 10-15l/min	0.300	84 (92.3%)	268 (96.1%)	0.149
Non-rebreather mask 10-15l/min duration, days	0.187	1 [0–3]	2 [1–3]	**0.001**
HFNO	0.825	53 (58.2%)	200 (71.7%)	**0.017**
HFNO duration, days	0.161	2 [1–4]	5 [2–9]	**<0.001**
NIV	0.404	17 (18.9%)	52 (18.6%)	0.958
NIV duration, days	**0.003**	3 [1–7]	3 [1–6]	0.871
IMV	0.134	68 (75.6%)	152 (54.5%)	**<0.001**
IMV duration, days	0.056	10 [6–17]	11 [6–17]	0.490
Lab test results				
CRP	**0.011**	150.4 [86.3–220.1]	113.9 [57.7–186.8]	**0.018**
Procalcitonin	**<0.001**	0.49 [0.19–1.21]	0.18 [0.09–0.66]	**<0.001**
Ferritin	**<0.001**	2116 [740–3340]	1146 [566–1672]	**0.004**
LDH	**<0.001**	772 [619–935]	464 [374–588]	**<0.001**
White blood count	**<0.001**	7.02 [4.66–9.04]	8.21 [5.81–10.97]	**0.002**
Neutrophils	**<0.001**	5.4 [3.7–7.9]	6.7 [4.2–9.4]	**0.010**
Lymphocytes	**<0.001**	0.8 [0.5–1.0]	0.9 [0.6–1.2]	**0.009**
Haemoglobin	0.089	13.2 [11.8–14.7]	13.5 [12.2–14.7]	0.512
Thrombocytes	**<0.001**	148 [116–183]	226 [172–297]	**<0.001**
D-dimer	0.286	1798 [1046–3442]	1366 [818–2644]	**0.034**
INR	0.848	1.12 [1.03–1.24]	1.08 [1.02–1.19]	0.122
AST	**<0.001**	74 [50–106]	50 [36–68]	**<0.001**
ALT	**<0.001**	43 [30–76]	37 [25–61]	**0.032**
Creatinine	**<0.001**	1.27 [0.87–1.79]	1 [0.8–1.32]	**0.002**